echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > ASN 2022: Endotrophin as a marker of complications in the type 2 diabetes cohort

    ASN 2022: Endotrophin as a marker of complications in the type 2 diabetes cohort

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hyperglycemia-mediated tissue damage eventually leads to fibrosis
    that affects various organ systems.
    We investigated whether serum and urine endotrophin, a pro-fibrosis signaling molecule, reflecting collagen VI formation, was associated with
    the risk of complications in unselected people with type 2 diabetes.

    Methods Endotrophin
    was measured by PRO-C6 ELISA in serum and urine of 774 patients with type 2 diabetes recruited between 2012 and 2016
    .
    Normalize urine values to urine creatinine levels
    .
    Results were determined by national registries and medical records, including composite renal endpoints (≥40% decline in renal function or renal failure), first major cardiovascular adverse event (MACE), all-cause mortality, progression of proteinuria, heart failure events, and vision-threatening eye disease
    .
    A Cox proportional risk model
    adjusted for general risk factors is applied.

    Results
    The cohort included 254 (33%) women with a mean age of ±SD of 65±12 years, a course of diabetes of 17±8.
    8 years, an eGFR of 76 ±24 ml/min/1.
    73 m2, and a median [Q1:Q3] urinary albumin excretion of 12.
    5 [5.
    5:73.
    5] mg/g or g/24 hours
    .
    Depending on the results, the median follow-up was 3.
    0 to 6.
    0 years
    .
    Doubling of serum endothelin was independently associated with composite renal endpoints, first MACE, all-cause mortality, and heart failure events, but not with progression of albuminuria or the development of vision-threatening eye disease (table).

    Doubling of endotrophin in urine was independently associated with the progression of albuminuria and heart failure events, but not with other outcomes (table).

    ConclusionsSerum
    endotrophin is a risk marker for
    mortality, renal and cardiovascular complications in patients with type 2 diabetes.
    Urotrophin is a risk marker for
    progression in proteinuria and heart failure events.

    Resources:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.